39 results on '"Duval-Modeste, Anne-Bénédicte"'
Search Results
2. A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type
- Author
-
Beylot-Barry, Marie, Mermin, Diane, Maillard, Aline, Bouabdallah, Reda, Bonnet, Nathalie, Duval-Modeste, Anne-Bénédicte, Mortier, Laurent, Ingen-Housz-Oro, Saskia, Ram-Wolff, Caroline, Barete, Stéphane, Dalle, Stéphane, Maubec, Eve, Quereux, Gaelle, Templier, Isabelle, Bagot, Martine, Grange, Florent, Joly, Pascal, Vergier, Béatrice, Vially, Pierre-Julien, Gros, Audrey, Pham-Ledard, Anne, Frison, Eric, and Merlio, Jean-Philippe
- Published
- 2018
- Full Text
- View/download PDF
3. Anti-PD-1 induced collagenous colitis in metastatic melanoma: a rare severe adverse event
- Author
-
Janela-Lapert, Raphaël, Bouteiller, Julie, Deschamps-Huvier, Aurélie, Duval-Modeste, Anne-Bénédicte, and Joly, Pascal
- Published
- 2020
- Full Text
- View/download PDF
4. Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature
- Author
-
Vuillamy, Chloé, Arnault, Jean-Philippe, Fumery, Mathurin, Mortier, Laurent, Monestier, Sandrine, Mansard, Sandrine, Bens, Guido, Duval-Modeste, Anne-Bénédicte, Funck-Brentano, Elisa, Jeudy, Géraldine, Machet, Laurent, Chaby, Guillaume, Dadban, Ali, Lok, Catherine, Université de Picardie Jules Verne (UPJV), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital de la Timone [CHU - APHM] (TIMONE), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Centre Hospitalier Régional d'Orléans (CHRO), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Hôpital Ambroise Paré [AP-HP], CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Dermatologie (CHU de Dijon), UMR 1253 IBrain Imagerie & Cerveau Equipe 3 'Imagerie, Biomarqueurs & Thérapie' (IBT), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Service de dermatologie [CHU d'Amiens-Picardie]
- Subjects
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; Immunotherapy has become the standard of care for several types of cancer, such as melanoma. However, it can induce toxicity, including immune checkpoint inhibitor-induced colitis (CIC). CIC shares several clinical, histological, biological, and therapeutic features with inflammatory bowel disease (IBD). Clostridium difficile infection (CDI) can complicate the evolution of IBD. We aimed to characterize the association between CDI and CIC in patients treated with anti-CTLA-4 and anti-PD-1 for melanoma. Patients from nine centers treated with anti-CTLA-4 and anti-PD-1 for melanoma and presenting with CDI from 2010 to 2021 were included in this retrospective cohort. The primary endpoint was the occurrence of CIC. The secondary endpoints were findings allowing us to characterize CDI. Eighteen patients were included. Eleven were treated with anti-PD-1, four with anti-CTLA-4, and three with anti-PD-1 in combination with anti-CTLA-4. Among the 18 patients, six had isolated CDI and 12 had CIC and CDI. Among these 12 patients, eight had CIC complicated by CDI, three had concurrent CIC and CDI, and one had CDI followed by CIC. CDI was fulminant in three patients. Endoscopic and histological features did not specifically differentiate CDI from CIC. Nine of 11 patients required immunosuppressive therapy when CDI was associated with CIC. In nine cases, immunotherapy was discontinued due to digestive toxicity. CDI can be isolated or can complicate or reveal CIC. CDI in patients treated with immunotherapy shares many characteristics with CDI complicating IBD. Stool tests for Clostridium difficile should be carried out for all patients with diarrhea who are being treated with immunotherapy.
- Published
- 2023
5. O-146 - Efficacy and tolerability of mogamulizumab in patients with mycosis fungoides or Sézary syndrome: retrospective and real-world data from centres of the French Study Group of Cutaneous Lymphoma
- Author
-
Beylot-Barry, Marie, Quereux, Gaelle, Nardin, Charlée, Duval-Modeste, Anne-Bénédicte, Dereure, Olivier, Dalac-Rat, Sophie, Dobis, Gabor, Pham-Ledard, Anne, Ram-Wolff, Caroline, D’Incan, Michel, Grange, Florent, Braniste, Viorica, and Bagot, Martine
- Published
- 2023
- Full Text
- View/download PDF
6. Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy
- Author
-
Tejedor, Ines, primary, Tedbirt, Billal, additional, Carvalho, Priscille, additional, Duval-Modeste, Anne Bénédicte, additional, Joly, Pascal, additional, and Hébert, Vivien, additional
- Published
- 2022
- Full Text
- View/download PDF
7. Metastatic porocarcinoma: A case demonstrating objective response to pembrolizumab
- Author
-
Benhayoun, Camélia, Duval Modeste, Anne Bénédicte, Tamarit, Clémence, Joly, Pascal, and Janela-Lapert, Raphaël
- Published
- 2024
- Full Text
- View/download PDF
8. Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study
- Author
-
Meyer, Nicolas, primary, Pérol, David, additional, Duval-Modeste, Anne-Bénédicte, additional, El Adaoui, Laïla, additional, Lelarge, Yoann, additional, Niarra, Ralph, additional, and Mateus, Christine, additional
- Published
- 2022
- Full Text
- View/download PDF
9. Outbreak of Mycobacterium chelonae in France
- Author
-
Goldman, Joana, Caron, François, de Quatrebarbes, Julie, Pestel-Caron, Martine, Courville, Philippe, Doré, Martin Xavier, Picard, Damien, Duval-Modeste, Anne-Bénédicte, Bravard, Pierre, and Joly, Pascal
- Published
- 2010
10. Clostridium difficileinfection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature
- Author
-
Vuillamy, Chloé, Arnault, Jean-Philippe, Fumery, Mathurin, Mortier, Laurent, Monestier, Sandrine, Mansard, Sandrine, Bens, Guido, Duval-Modeste, Anne-Bénédicte, Funck-Brentano, Elisa, Jeudy, Géraldine, Machet, Laurent, Chaby, Guillaume, Dadban, Ali, and Lok, Catherine
- Abstract
Immunotherapy has become the standard of care for several types of cancer, such as melanoma. However, it can induce toxicity, including immune checkpoint inhibitor–induced colitis (CIC). CIC shares several clinical, histological, biological, and therapeutic features with inflammatory bowel disease (IBD). Clostridium difficileinfection (CDI) can complicate the evolution of IBD. We aimed to characterize the association between CDI and CIC in patients treated with anti-CTLA-4 and anti-PD-1 for melanoma. Patients from nine centers treated with anti-CTLA-4 and anti-PD-1 for melanoma and presenting with CDI from 2010 to 2021 were included in this retrospective cohort. The primary endpoint was the occurrence of CIC. The secondary endpoints were findings allowing us to characterize CDI. Eighteen patients were included. Eleven were treated with anti-PD-1, four with anti-CTLA-4, and three with anti-PD-1 in combination with anti-CTLA-4. Among the 18 patients, six had isolated CDI and 12 had CIC and CDI. Among these 12 patients, eight had CIC complicated by CDI, three had concurrent CIC and CDI, and one had CDI followed by CIC. CDI was fulminant in three patients. Endoscopic and histological features did not specifically differentiate CDI from CIC. Nine of 11 patients required immunosuppressive therapy when CDI was associated with CIC. In nine cases, immunotherapy was discontinued due to digestive toxicity. CDI can be isolated or can complicate or reveal CIC. CDI in patients treated with immunotherapy shares many characteristics with CDI complicating IBD. Stool tests for Clostridium difficileshould be carried out for all patients with diarrhea who are being treated with immunotherapy.
- Published
- 2023
- Full Text
- View/download PDF
11. Résultats finaux d’une cohorte de 705 patients atteints de mélanome avancé et ayant débuté un traitement par pembrolizumab au cours de son programme français d’ATU
- Author
-
Meyer, Nicolas, primary, Aubin, François, additional, Benmahammed-Bellagha, Lynda, additional, Brunet-Possenti, Florence, additional, Dereure, Olivier, additional, Dutriaux, Caroline, additional, Duval-Modeste, Anne-Bénédicte, additional, Grange, Florent, additional, Grob, Jean-Jacques, additional, Kramkimel, Nora, additional, Lattenist, Lionel, additional, Leccia, Marie-Thérèse, additional, Machet, Laurent, additional, Mortier, Laurent, additional, Neidhardt, Eve-Marie, additional, Robert, Caroline, additional, Scherrer, Emilie, additional, Spampinato, Axelle, additional, Verdoni, Laetitia, additional, and Saiag, Philippe, additional
- Published
- 2021
- Full Text
- View/download PDF
12. Infection à Clostridium difficile et colite auto-immune sous immunothérapie dans le mélanome : étude rétrospective de 18 cas
- Author
-
Vuillamy, Chloé, primary, Arnault, Jean-Philippe, additional, Fumery, Mathurin, additional, Mortier, Laurent, additional, Monestier, Sandrine, additional, Mansard, Sandrine, additional, Bens, Guido, additional, Duval-Modeste, Anne-Bénédicte, additional, Funck-Brentano, Elisa, additional, Jeudy, Géraldine, additional, Machet, Laurent, additional, Chaby, Guillaume, additional, Dadban, Ali, additional, and Lok, Catherine, additional
- Published
- 2021
- Full Text
- View/download PDF
13. COVID-19 : adhésion à la vaccination chez des patients immunodéprimés de dermatologie
- Author
-
Lafon, Audrey, primary, Mignard, Claire, additional, Castel, Marion, additional, Duval-Modeste, Anne-Bénédicte, additional, and Joly, Pascal, additional
- Published
- 2021
- Full Text
- View/download PDF
14. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy
- Author
-
Hamieh, Mohamad, primary, Chatillon, Jean-François, additional, Dupel, Estelle, additional, Bayeux, Florence, additional, Fauquembergue, Emilie, additional, Maby, Pauline, additional, Drouet, Aurelie, additional, Duval-Modeste, Anne-Bénédicte, additional, Adriouch, Sahil, additional, Boyer, Olivier, additional, and Latouche, Jean-Baptiste, additional
- Published
- 2021
- Full Text
- View/download PDF
15. Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group
- Author
-
Hober, Candice, primary, Fredeau, Lisa, additional, Pham-Ledard, Anne, additional, Boubaya, Marouane, additional, Herms, Florian, additional, Celerier, Philippe, additional, Aubin, François, additional, Beneton, Nathalie, additional, Dinulescu, Monica, additional, Jannic, Arnaud, additional, Meyer, Nicolas, additional, Duval-Modeste, Anne-Bénédicte, additional, Cesaire, Laure, additional, Neidhardt, Ève-Marie, additional, Archier, Élodie, additional, Dréno, Brigitte, additional, Lesage, Candice, additional, Berthin, Clémence, additional, Kramkimel, Nora, additional, Grange, Florent, additional, de Quatrebarbes, Julie, additional, Stoebner, Pierre-Emmanuel, additional, Poulalhon, Nicolas, additional, Arnault, Jean-Philippe, additional, Abed, Safia, additional, Bonniaud, Bertille, additional, Darras, Sophie, additional, Heidelberger, Valentine, additional, Devaux, Suzanne, additional, Moncourier, Marie, additional, Misery, Laurent, additional, Mansard, Sandrine, additional, Etienne, Maxime, additional, Brunet-Possenti, Florence, additional, Jacobzone, Caroline, additional, Lesbazeilles, Romain, additional, Skowron, François, additional, Sanchez, Julia, additional, Catala, Stéphanie, additional, Samimi, Mahtab, additional, Tazi, Youssef, additional, Spaeth, Dominique, additional, Gaudy-Marqueste, Caroline, additional, Collard, Olivier, additional, Triller, Raoul, additional, Pracht, Marc, additional, Dumas, Marc, additional, Peuvrel, Lucie, additional, Combe, Pierre, additional, Lauche, Olivier, additional, Guillet, Pierre, additional, Reguerre, Yves, additional, Kupfer-Bessaguet, Ingrid, additional, Solub, David, additional, Schoeffler, Amélie, additional, Bedane, Christophe, additional, Quéreux, Gaëlle, additional, Dalac, Sophie, additional, Mortier, Laurent, additional, and Maubec, Ève, additional
- Published
- 2021
- Full Text
- View/download PDF
16. Association of occupational exposure with features of systemic sclerosis
- Author
-
Marie, Isabelle, Menard, Jean-François, Duval-Modeste, Anne-Bénédicte, Joly, Pascal, Dominique, Stéphane, Bravard, Pierre, Noël, David, Gehanno, Jean-François, Bubenheim, Michael, Benichou, Jacques, and Levesque, Hervé
- Published
- 2015
- Full Text
- View/download PDF
17. Lack of association between chilblains outbreak and severe acute respiratory syndrome coronavirus 2: Histologic and serologic findings from a new immunoassay
- Author
-
Hébert, Vivien, primary, Duval-Modeste, Anne-Bénédicte, additional, Joly, Pascal, additional, Lemée, Véronique, additional, Cellier, Lucie, additional, Jouen, Fabienne, additional, Veber, Benoit, additional, Drouot, Laurent, additional, and Boyer, Olivier, additional
- Published
- 2020
- Full Text
- View/download PDF
18. Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study
- Author
-
Montaudié, Henri, primary, Viotti, Julien, additional, Combemale, Patrick, additional, Dutriaux, Caroline, additional, Dupin, Nicolas, additional, Robert, Caroline, additional, Mortier, Laurent, additional, Kaphan, Régis, additional, Duval-Modeste, Anne-Bénédicte, additional, Dalle, Stéphane, additional, De Quatrebarbes, Julie, additional, Stefan, Andrea, additional, Brunet-Possenti, Florence, additional, Kogay, Maria, additional, Picard-Gauci, Alexandra, additional, Poissonnet, Gilles, additional, and Peyrade, Frédéric, additional
- Published
- 2020
- Full Text
- View/download PDF
19. Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study.
- Author
-
Monestier, Sandrine, Dalle, Stéphane, Mortier, Laurent, Dutriaux, Caroline, Dalac‐Rat, Sophie, Meyer, Nicolas, Leccia, Marie Thérèse, Mansard, Sandrine, Montaudié, Henri, Saiag, Philippe, Combemale, Patrick, Guillot, Bernard, Skowron, François, Duval Modeste, Anne‐Bénédicte, Bénéton, Nathalie, Hainaut, Ewa, Robert, Caroline, Arnault, Jean Philippe, Le Corre, Yannick, and Jouary, Thomas
- Subjects
PATIENT safety ,DRUG efficacy ,MELANOMA ,SCIENTIFIC observation ,PROGRESSION-free survival - Abstract
This retrospective observational study aimed to determine the effectiveness, safety and patterns of the use of nivolumab in patients with advanced melanoma in real‐world clinical practice in France using data from a Temporary Authorization for Use Program (ATU). Data were collected from patients with unresectable or metastatic melanoma enrolled in a French national database (Réseau pour la Recherche et l'Investigation Clinique sur le Mélanome: Ric‐Mel) and treated with nivolumab during the ATU program (12 September 2014 to 31 August 2015). The primary objectives of the study were to evaluate the effect of patient characteristics on clinical response and overall survival (OS). Among 400 included patients (median age 66 years), the majority (83%) received nivolumab as second‐ or subsequent‐line therapy. The median durations of progression‐free survival and OS were 3.3 and 14.1 months, respectively, and 31.6% of patients achieved an objective response with a median duration of 20.1 months (range: 0‐34.7). The safety profile of nivolumab was manageable and consistent with those of previous clinical trials, with an incidence of grade 3‐5 adverse events of 13.8%. The safety and effectiveness of nivolumab in patients with advanced melanoma in real‐world clinical practice in France were in line with the data reported in the Phase 3 trials CheckMate 066 and 037 of nivolumab in this patient population. What's new? Clinical trial data support the use of nivolumab in melanoma patients, and the drug received a Temporary Authorization for Use in France. Here, the authors present real‐world clinical data on the safety and efficacy of nivolumab collected from 400 patients with unresectable or metastatic melanoma. They found that the safety and efficacy in the real world context was consistent with the profile reported in phase 3 trials. The study also includes data from some sub‐populations that may have been underrepresented in the clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort
- Author
-
Faiz, Sarah, primary, Giovannelli, Jonathan, additional, Podevin, Céline, additional, Jachiet, Marie, additional, Bouaziz, Jean-David, additional, Reguiai, Ziad, additional, Nosbaum, Audrey, additional, Lasek, Audrey, additional, Ferrier le Bouedec, Marie-Christine, additional, Du Thanh, Aurélie, additional, Raison-Peyron, Nadia, additional, Tetart, Florence, additional, Duval-Modeste, Anne-Bénédicte, additional, Misery, Laurent, additional, Aubin, François, additional, Dompmartin, Anne, additional, Morice, Cécile, additional, Droitcourt, Catherine, additional, Soria, Angèle, additional, Arnault, Jean-Philippe, additional, Delaunay, Juliette, additional, Mahé, Emmanuel, additional, Richard, Marie-Aleth, additional, Schoeffler, Amélie, additional, Lacour, Jean-Philippe, additional, Begon, Edouard, additional, Walter-Lepage, Amélie, additional, Dillies, Anne-Sophie, additional, Rappelle-Duruy, Sandrine, additional, Barete, Stéphane, additional, Bellon, Nathalia, additional, Bénéton, Nathalie, additional, Valois, Aude, additional, Barbarot, Sébastien, additional, Sénéchal, Julien, additional, and Staumont-Sallé, Delphine, additional
- Published
- 2019
- Full Text
- View/download PDF
21. Ipilimumab-induced severe meningoradiculitis
- Author
-
Lacour, Morgane, primary, Grangeon, Lou, additional, Flament, Jasmine, additional, Duval-Modeste, Anne-Bénédicte, additional, Zaréa, Aline, additional, Guillaume, Maxime, additional, and Lefaucheur, Romain, additional
- Published
- 2019
- Full Text
- View/download PDF
22. Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors
- Author
-
Puechal, Xavier, Pagnoux, Christian, Baron, Gabriel, Quemeneur, Thomas, Néel, Antoine, Agard, Christian, Lifermann, François, Liozon, Eric, Ruivard, Marc, Godmer, Pascal, Limal, Nicolas, Mekinian, Arsène, Papo, Thomas, Ruppert, Anne, Bourgarit, Anne, Bienvenu, Boris, Geffray, Loïc, Saraux, Luc, Diot, Elisabeth, Crestani, Bruno, Delbrel, Xavier, Sailler, Laurent, Cohen, Pascal, Le Guern, Véronique, Terrier, Benjamin, Groh, Matthieu, Le Jeunne, Claire, Mouthon, Luc, Ravaud, Philippe, Guillevin, Loïc, Pineton de Chambrun, Marc, Luyt, Charles-Edouard, Beloncle, Francois, Gousseff, Marie, Mauhin, Wladimir, Argaud, Laurent, Ledochowski, Stanislas, Moreau, Anne-Sophie, Sonneville, Romain, Verdière, Bruno, Merceron, Sybille, Zappella, Nathalie, Landais, Mickael, Contou, Damien, Demoule, Alexandre, Paulus, Sylvie, Souweine, Bertrand, Lecomte, Bernard, Vieillard-Baron, Antoine, Terzi, Nicolas, Azoulay, Elie, Friolet, Raymond, Puidupin, Marc, Devaquet, Jérôme, Mazou, Jean-Marc, Fédun, Yannick, Mira, Jean-Paul, Raphalen, Jean-Herlé, Combes, Alain, Amoura, Zahir, Lega, Jean-Christophe, Lambert, Marc, Rivière, Sophie, Dossier, Antoine, Lhote, François, Blaison, Gilles, Alric, Laurent, Saadoun, David, Graveleau, Julie, Soubrier, Martin, Lecomte, Marie-Josée, Christides, Christine, Bosseray, Annick, Lévesque, Hervé, Viallard, François, Tieulie, Nathalie, Lovey, Pierre-Yves, Le Moal, Sylvie, Bibes, Béatrice, Malizia, Giuseppe, Abgueguen, Pierre, Liferman, François, Ninet, Jacques, Hatron, Pierre-Yves, Hot, Arnaud, Hernu, Romain, de La Salle, Sylvie, Similowski, Thomas, Haroche, Julien, Boileau, Julien, Hanslik, Thomas, Bulte, Caroline, Talasczka, Aline, Hachulla, Eric, Decaux, Olivier, Ibouanga, Florent, Arnulf, Bertrand, Benedit, Marc, Maalouf, Assaad, Moulin, Bruno, Cohen-Aubart, Fleur, Pha, Micheline, Rivard, Georges-Etienne, Rondeau, Eric, Debourdeau, Philippe, Presne, Claire, Andrieu, Maude, Len Abad, Oscar, Devilliers, Hervé, Rogers, Alister, Hie, Miguel, Mathian, Alexis, Heidelberger, Valentine, Ingen-Housz-Oro, Saskia, Marquet, Alicia, Mahevas, Matthieu, Bessis, Didier, Bouillet, Laurence, Caux, Frédéric, Chapelon-Abric, Catherine, Debarbieux, Sebastien, Delaporte, Emmanuel, Duval-Modeste, Anne-Bénédicte, Fain, Olivier, Joly, Pascal, Marchand-Adam, Marc, Monfort, Jean-Benoît, Noel, Nicolas, Passeron, Thierry, Sarrot-Reynauld, Françoise, Verrot, Denis, Bouvry, Diane, Fardet, Laurence, Chosidow, Olivier, Sève, Pascal, Valeyre, Dominique, Moreau, Sophie, Centre Hospitalier Le Mans (CH Le Mans), Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Département de Médecine Interne (VALENCIENNES - Med Int), CH Valenciennes, Service de médecine interne [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Médecine Interne [Dax], Centre Hospitalier de Dax, Service de Médecine interne A et polyclinique médicale [CHU Limoges], CHU Limoges, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Service de médecine interne [CHU Bretagnes Atlantique], CHU Bretagnes Atlantique, Service de rhumatologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Department of Internal Medicine, Université Paris Diderot - Paris 7 (UPD7), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Médecine interne, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Physiopathologie et Epidemiologie de l'Insuffisance Respiratoire, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Médecine Interne [Pau], Centre hospitalier de Pau, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Immunologie - Immunopathologie - Immunothérapeutique (I3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service des maladies infectieuses et tropicales, Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Chirurgie Orthopédique et traumatique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre de référence pour les vascularites nécrosantes et la sclérodermie systémique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Faculté de Médecine-pôle de Médecine Interne, CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Réanimation Médicale et de Médecine Hyperbare [Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Institut Pasteur de Madagascar, Réseau International des Instituts Pasteur (RIIP), Centre de recherche en myologie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Ecole Polytechnique Fédérale de Lausanne (EPFL), Hôpital Bichat - Claude Bernard, Service de soins intensifs, Centre Hospitalier de Versailles André Mignot (CHV), Service de réanimation médicale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Neurophysiologie Respiratoire Expérimentale et Clinique, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Microorganismes : Génome et Environnement (LMGE), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Centre National de la Recherche Scientifique (CNRS)-Université d'Auvergne - Clermont-Ferrand I (UdA), Médecine générale, Service de réanimation medico-chirurgicale [CHU Raymond-Poincaré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Service de réanimation médicale [CHU Caen], Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Medical ICU, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service d'anesthésie-réanimation SAMU94-SMUR94 [Mondor], Institut Cochin (UMR_S567 / UMR 8104), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Immunité et Infection, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Centre National de la Recherche Scientifique (CNRS), Hôpital pasteur [Colmar], Service de Medecine Interne, CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Centre hospitalier de Saint-Nazaire, Clinique de médecine interne, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Service de Médecine Interne [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Hôpital l'Archet, Service des maladies infectieuses et tropicales [CHU Angers], Médecine Interne Dax (MEDECINE INTERNE), Hopital, Service de Médecine Interne, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de médecine interne [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Pneumologie et Réanimation Médicale [CHU Pitié-Salpêtrière] (Département ' R3S '), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de médecine interne [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Department of Clinical Immunology, CHU Strasbourg, CHU Pontchaillou [Rennes], Service d'hématologie biologique, Service de néphrologie, Service de médecine interne et d'immunologie clinique [CHU Pitié-Salpêtrière], Service d'Hématologie-Oncologie, Hôpital Ste-Justine, Département d'Oncologie (Dep Oncol - AVIGNON), Institut Ste Catherine, Service de Néphrologie - Médecine Interne, CHU Amiens-Picardie-hôpital Sud, Service de Médecine Interne (SOC 1 et SOC 2) [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Henri Mondor, Service de Médecine Interne [Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Centre de référence maladie rare des cytopénies auto-immunes de l'adulte-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de Dermatologie, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de dermatologie [Avicenne], Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13), Service de Dermatologie, Centre Hospitalier Sud, Hospices Civils, Lyon, Service de dermatologie (CHRU de Lille), Service de dermatologie [Rouen], Service de médecine interne, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Jean Verdier [AP-HP], Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information (CEA-LETI), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Equipe 12, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet-Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet-Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Service de pneumologie [Avicenne], Service de médecine interne [Saint-Antoine], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Centre de recherche en Myologie – U974 SU-INSERM, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Centre National de la Recherche Scientifique (CNRS), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service Médecine interne [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Henri Mondor [Créteil], Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (1965 - 2019) (UNS), Hôpital Ambroise Paré [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR113-Université Pierre et Marie Curie - Paris 6 (UPMC), Service de Département de médecine interne et immunologie clinique [CHU Pitié-Salpêtrière] (DMIIC), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Service de médecine interne [CHU Saint-Antoine]
- Subjects
[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system ,[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience
- Published
- 2017
23. Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
- Author
-
Mignard, Claire, primary, Deschamps Huvier, Aurélie, additional, Gillibert, André, additional, Duval Modeste, Anne Bénédicte, additional, Dutriaux, Caroline, additional, Khammari, Amir, additional, Avril, Marie-Françoise, additional, Kramkimel, Nora, additional, Mortier, Laurent, additional, Marcant, Pierre, additional, Lesimple, Thierry, additional, Gaudy-Marqueste, Caroline, additional, Lesage, Candice, additional, Machet, Laurent, additional, Aubin, François, additional, Meyer, Nicolas, additional, Beneton, Nathalie, additional, Jeudy, Géraldine, additional, Montaudié, Henri, additional, Arnault, Jean-Philippe, additional, Visseaux, Laetitia, additional, Trabelsi, Sabiha, additional, Amini-Adle, Mona, additional, Maubec, Eve, additional, Le Corre, Yannick, additional, Lipsker, Dan, additional, Wierzbicka-Hainaut, Ewa, additional, Litrowski, Noémie, additional, Stefan, Andreea, additional, Brunet-Possenti, Florence, additional, Leccia, Marie-Thérèse, additional, and Joly, Pascal, additional
- Published
- 2018
- Full Text
- View/download PDF
24. Efficacy and Tolerance of Anti–Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis
- Author
-
RUIVARD, Marc, Heidelberger, Valentine, Ingen-Housz-Oro, Saskia, Marquet, Alicia, Mahevas, Matthieu, Bessis, Didier, Bouillet, Laurence, Caux, Frédéric, Chapelon-Abric, Catherine, Debarbieux, Sebastien, Delaporte, Emmanuel, Duval-Modeste, Anne-Bénédicte, Fain, Olivier, Joly, Pascal, Marchand-Adam, Marc, Monfort, Jean-Benoît, Noel, Nicolas, Passeron, Thierry, Sarrot-Reynauld, Françoise, Verrot, Denis, Bouvry, Diane, Fardet, Laurence, Chosidow, Olivier, Sève, Pascal, Valeyre, Dominique, Institut Pascal (IP), SIGMA Clermont (SIGMA Clermont)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), CHU Henri Mondor, Service de Médecine Interne [Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Centre de référence maladie rare des cytopénies auto-immunes de l'adulte-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de Dermatologie, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Clinique de médecine interne, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Service de dermatologie [Avicenne], Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de médecine interne et d'immunologie clinique [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université, Service de Dermatologie, Centre Hospitalier Sud, Hospices Civils, Lyon, Service de dermatologie (CHRU de Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de dermatologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de médecine interne, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Jean Verdier [AP-HP], Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information (CEA-LETI), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Equipe 12, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet-Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet-Centre méditerranéen de médecine moléculaire (C3M), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA), Service de pneumologie [Avicenne], Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de médecine interne [Saint-Antoine], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Sorbonne Université, Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hospices Civils de Lyon (HCL), Service de Département de médecine interne et immunologie clinique [CHU Pitié-Salpêtrière] (DMIIC), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Jean Verdier [AP-HP], Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Université de Tours (UT), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Service de médecine interne [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Centre de référence maladie rare des cytopénies auto-immunes de l'adulte-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Avicenne, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris 13 (UP13)-Hôpital Jean Verdier [Bondy], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), INSERM U1234, Université de Tours, Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Avicenne, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13)-Hôpital Jean Verdier [AP-HP], Institut Pascal - Clermont Auvergne (IP), Sigma CLERMONT (Sigma CLERMONT)-Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Jean Verdier [Bondy], Laboratoire d'Electronique et des Technologies de l'Information (CEA-LETI), and Université Grenoble Alpes (UGA)-Direction de Recherche Technologique (CEA) (DRT (CEA))
- Subjects
[SDV]Life Sciences [q-bio] ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience; Evidence for the long-term efficacy and safety of anti-tumor necrosis factor α agents (anti-TNF) in treating cutaneous sarcoidosis is lacking.
- Published
- 2017
25. Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib
- Author
-
Pinard, Camille, primary, Mignard, Claire, additional, Samain, Agnès, additional, Duval-Modeste, Anne-Bénédicte, additional, and Joly, Pascal, additional
- Published
- 2017
- Full Text
- View/download PDF
26. Efficacy and Tolerance of Anti–Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis
- Author
-
Heidelberger, Valentine, primary, Ingen-Housz-Oro, Saskia, additional, Marquet, Alicia, additional, Mahevas, Matthieu, additional, Bessis, Didier, additional, Bouillet, Laurence, additional, Caux, Frédéric, additional, Chapelon-Abric, Catherine, additional, Debarbieux, Sébastien, additional, Delaporte, Emmanuel, additional, Duval-Modeste, Anne-Bénédicte, additional, Fain, Olivier, additional, Joly, Pascal, additional, Marchand-Adam, Sylvain, additional, Monfort, Jean-Benoît, additional, Noël, Nicolas, additional, Passeron, Thierry, additional, Ruivard, Marc, additional, Sarrot-Reynauld, Françoise, additional, Verrot, Denis, additional, Bouvry, Diane, additional, Fardet, Laurence, additional, Chosidow, Olivier, additional, Sève, Pascal, additional, and Valeyre, Dominique, additional
- Published
- 2017
- Full Text
- View/download PDF
27. Controlling the digital ulcerative disease in systemic sclerosis is associated with improved hand function
- Author
-
Mouthon, Luc, primary, Carpentier, Patrick H., additional, Lok, Catherine, additional, Clerson, Pierre, additional, Gressin, Virginie, additional, Hachulla, Eric, additional, Bérezné, Alice, additional, Diot, Elisabeth, additional, Van Kien, Aurélie Khau, additional, Jego, Patrick, additional, Agard, Christian, additional, Duval-Modeste, Anne-Bénédicte, additional, Sparsa, Agnès, additional, Puzenat, Eve, additional, and Richard, Marie-Aleth, additional
- Published
- 2017
- Full Text
- View/download PDF
28. Interstitial pneumonia after infliximab therapy for psoriasis
- Author
-
Leger, Sandy, Etienne, Manuel, Duval-Modeste, Anne-Bénédicte, Roussel, Aude, Caron, François, Thiberville, Luc, Service des maladies infectieuses et tropicales [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de dermatologie [Rouen], Service de pharmacologie [CHU Rouen], Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), and Breton, Céline
- Subjects
ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2011
29. First case of drug rash eosinophilia and systemic symptoms due to boceprevir
- Author
-
Samain, Agnès, primary, Duval-Modeste, Anne-Bénédicte, additional, Joly, Pascal, additional, Leblanc, Céline, additional, Massy, Nathalie, additional, Courville, Philippe, additional, Goria, Odile, additional, and Riachi, Ghassan, additional
- Published
- 2014
- Full Text
- View/download PDF
30. Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
- Author
-
Maubec, Eve, primary, Petrow, Peter, additional, Scheer-Senyarich, Isabelle, additional, Duvillard, Pierre, additional, Lacroix, Ludovic, additional, Gelly, Julien, additional, Certain, Agnès, additional, Duval, Xavier, additional, Crickx, Béatrice, additional, Buffard, Valérie, additional, Basset-Seguin, Nicole, additional, Saez, Pierre, additional, Duval-Modeste, Anne-Bénédicte, additional, Adamski, Henri, additional, Mansard, Sandrine, additional, Grange, Florent, additional, Dompmartin, Anne, additional, Faivre, Sandrine, additional, Mentré, France, additional, and Avril, Marie-Françoise, additional
- Published
- 2011
- Full Text
- View/download PDF
31. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome à l’oxcarbazépine mimant un choc septique
- Author
-
Chakarian, Jean-Charles, primary, Girault, Christophe, additional, Béduneau, Gaëtan, additional, Duval-Modeste, Anne-Bénédicte, additional, Joly, Pascal, additional, and Bonmarchand, Guy, additional
- Published
- 2010
- Full Text
- View/download PDF
32. Unusual presentation of oropharyngeal Kaposi's sarcoma
- Author
-
Choussy, Olivier, primary, Haverbeke, Christophe Van, additional, Babin, Emmanuel, additional, Francois, Arnaud, additional, Duval‐Modeste, Anne Bénédicte, additional, and Dehesdin, Daniele, additional
- Published
- 2007
- Full Text
- View/download PDF
33. Ischemic Digital Ulcers Affect Hand Disability and Pain in Systemic Sclerosis.
- Author
-
Mouthon, Luc, Carpentier, Patrick H., Lok, Catherine, Clerson, Pierre, Gressin, Virginie, Hachulla, Eric, Bérezné, Alice, Diot, Elisabeth, Van Kien, Aurélie Khau, Jego, Patrick, Agard, Christian, Duval-Modeste, Anne Bénédicte, Sparsa, Agnès, Puzenat, Eve, and Richard, Marie-Aleth
- Published
- 2014
- Full Text
- View/download PDF
34. Unusual presentation of oropharyngeal Kaposi's sarcoma.
- Author
-
Choussy, Olivier, Haverbeke, Christophe Van, Babin, Emmanuel, Francois, Arnaud, Duval-Modeste, Anne Bénédicte, and Dehesdin, Daniele
- Subjects
KAPOSI'S sarcoma ,DEGLUTITION disorders ,HOARSENESS ,LARYNGEAL diseases ,BLEOMYCIN - Abstract
Background. The aim of this article is to focus ear, nose, and throat (ENT) practitioners on a pathology rarely seen within the head and neck mucosa. Methods. A 62-year-old black African man was referred to our ENT department for dysphagia and hoarseness. Physical ENT examination revealed a smooth normal mucosal mass on the left lateral pharyngeal wall, which masked the inlet of the larynx, and bilateral cervical lymph nodes but no other mucosal lesions. Anti–human immunodeficiency virus antibodies were found to be negative. Hemoglobin, hematocrit, white blood cell count, and platelet count were normal. Serum protein electrophoresis was also normal. A CT scan confirmed the lesion and lymph node involvement. Treatment consisted of a transoral endoscopic resection with ligature of the pedicle, with the patient under general anesthesia. The patient's improved medical condition permitted 11 cycles of bleomycin (15 mg/3 weeks). Results. A 5-month fibroscopic follow-up control showed no recurrence, and total clinical regression was observed after 1 year. Three years later, all ENT lesions had disappeared, with no adenopathy or mucosal lesions. Conclusion. Kaposi's sarcoma is a pathology that the ENT practitioner must keep in mind when patients present with a laryngopharyngeal mass. The symptomatic cases were all surgically treated; however, death subsequently occurred. © 2007 Wiley Periodicals, Inc. Head Neck 2008 [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
35. Infection à Clostridium difficileet colite auto-immune sous immunothérapie dans le mélanome : étude rétrospective de 18 cas
- Author
-
Vuillamy, Chloé, Arnault, Jean-Philippe, Fumery, Mathurin, Mortier, Laurent, Monestier, Sandrine, Mansard, Sandrine, Bens, Guido, Duval-Modeste, Anne-Bénédicte, Funck-Brentano, Elisa, Jeudy, Géraldine, Machet, Laurent, Chaby, Guillaume, Dadban, Ali, and Lok, Catherine
- Abstract
L’immunothérapie est utilisée en soins courants dans le traitement du mélanome et peut être à l’origine d’effets indésirables telle qu’une colite auto-immune (CAI). Les CAI partagent des similarités cliniques, histologiques, biologiques et thérapeutiques avec les maladies inflammatoires chroniques de l’intestin (MICI) tout en s’en distinguant. L’infection à Clostridium difficile(CD) complique classiquement les MICI. Par analogie, le but de ce travail était d’étudier le lien entre CAI et infection à CD sous immunothérapie pour un mélanome.
- Published
- 2021
- Full Text
- View/download PDF
36. INFECTIONS FROM TATTOOING: Outbreak of Mycobacterium chelonae in France.
- Author
-
Goldman, Joana, Caron, François, de Quatrebarbes, Julie, Pestel-Caron, Martine, Courville, Philippe, Doré, Martin Xavier, Picard, Damien, Duval-Modeste, Anne-Bénédicte, Bravard, Pierre, and Joly, Pascal
- Subjects
LETTERS to the editor ,MYCOBACTERIAL diseases ,TATTOOING - Abstract
A letter to the editor is presented about a large outbreak of Mycobacterium chelonae skin infection in France in relation to tattooing.
- Published
- 2010
37. Clostridium difficile infection and immune checkpoint inhibitor-induced colitis in melanoma: 18 cases and a review of the literature.
- Author
-
Vuillamy C, Arnault JP, Fumery M, Mortier L, Monestier S, Mansard S, Bens G, Duval-Modeste AB, Funck-Brentano E, Jeudy G, Machet L, Chaby G, Dadban A, and Lok C
- Subjects
- Humans, Immune Checkpoint Inhibitors therapeutic use, Retrospective Studies, Melanoma complications, Melanoma drug therapy, Skin Neoplasms complications, Skin Neoplasms drug therapy, Colitis chemically induced, Colitis drug therapy, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases epidemiology, Clostridium Infections complications, Clostridium Infections drug therapy, Clostridium Infections epidemiology
- Abstract
Immunotherapy has become the standard of care for several types of cancer, such as melanoma. However, it can induce toxicity, including immune checkpoint inhibitor-induced colitis (CIC). CIC shares several clinical, histological, biological, and therapeutic features with inflammatory bowel disease (IBD). Clostridium difficile infection (CDI) can complicate the evolution of IBD. We aimed to characterize the association between CDI and CIC in patients treated with anti-CTLA-4 and anti-PD-1 for melanoma. Patients from nine centers treated with anti-CTLA-4 and anti-PD-1 for melanoma and presenting with CDI from 2010 to 2021 were included in this retrospective cohort. The primary endpoint was the occurrence of CIC. The secondary endpoints were findings allowing us to characterize CDI. Eighteen patients were included. Eleven were treated with anti-PD-1, four with anti-CTLA-4, and three with anti-PD-1 in combination with anti-CTLA-4. Among the 18 patients, six had isolated CDI and 12 had CIC and CDI. Among these 12 patients, eight had CIC complicated by CDI, three had concurrent CIC and CDI, and one had CDI followed by CIC. CDI was fulminant in three patients. Endoscopic and histological features did not specifically differentiate CDI from CIC. Nine of 11 patients required immunosuppressive therapy when CDI was associated with CIC. In nine cases, immunotherapy was discontinued due to digestive toxicity. CDI can be isolated or can complicate or reveal CIC. CDI in patients treated with immunotherapy shares many characteristics with CDI complicating IBD. Stool tests for Clostridium difficile should be carried out for all patients with diarrhea who are being treated with immunotherapy., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
38. Infections from tattooing. Outbreak of Mycobacterium chelonae in France.
- Author
-
Goldman J, Caron F, de Quatrebarbes J, Pestel-Caron M, Courville P, Doré MX, Picard D, Duval-Modeste AB, Bravard P, and Joly P
- Subjects
- France epidemiology, Humans, Disease Outbreaks, Ink, Mycobacterium Infections, Nontuberculous epidemiology, Mycobacterium chelonae, Tattooing adverse effects
- Published
- 2010
- Full Text
- View/download PDF
39. [Oxcarbazepine Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome mimicking septic shock].
- Author
-
Chakarian JC, Girault C, Béduneau G, Duval-Modeste AB, Joly P, and Bonmarchand G
- Subjects
- Carbamazepine adverse effects, Diagnosis, Differential, Drug Eruptions diagnosis, Drug Eruptions therapy, Eosinophilia diagnosis, Eosinophilia therapy, Female, Humans, Middle Aged, Multiple Organ Failure chemically induced, Oxcarbazepine, Shock, Septic diagnosis, Syndrome, Anticonvulsants adverse effects, Carbamazepine analogs & derivatives, Drug Eruptions etiology, Eosinophilia chemically induced
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.